Text Size

Rotenone-Induced Optic Nerve Damage and Retinal Ganglion Cell Loss in Rats

Yamamoto Y.; Taniguchi T.; Shimazaki A.


  • 2024
  • Biomolecules
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Preclinical development

  • Affiliations

    Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, 630-0101, Japan; Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Nara, 630-0101, Japan

Related Publications

The growing burden of myopia in Europe: evidence from population-based cohorts

Tiemens A., van Hemert D.J., Lemma S.T., Quist S.W., Shi-van Wielink K., Agius D., Arnould L., Berendschot T.T.J.M., Beuse A., Bikbov M.M., Birtel J., Bountziouka V., Breteler M.M.B., Carbonaro F., Chakravarthy U., Coimbra R., de Vries V.A., Delcourt C., Farinha C., Finger R.P., Ghanbari M., Giannoulis D.A., Grohmann C., Hammond C.J., European Eye Epidemiology (E3) Consortium


Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes

Jovanović J., Zacharioudaki M., Kalatzi M., Papadakis G., Mulkalapalli N., Ernst F., de Milliano T.


Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022